Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on VYNE Therapeutics and keeping the price target at $4.50.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding VYNE Therapeutics’ recent developments. The company’s VYN202 program has shown promising signs of activity and safety, even after the FDA’s clinical hold on the Phase 1b trial for moderate-to-severe plaque psoriasis. The hold was initially due to testicular toxicity findings in dogs, but the FDA allowed the study to resume in female patients at certain doses, which showed no adverse effects.
Furthermore, the unblinded data from the trial indicated that patients treated with VYN202 experienced significant improvements in disease symptoms without serious side effects. Notably, reductions in Psoriasis Area and Severity Index (PASI) scores and serum cytokines were observed, alongside improvements in psoriatic arthritis symptoms. These early efficacy signals, coupled with the company’s strategic decision to close enrollment in the Phase 1b study to extend its cash runway, contribute to the optimistic outlook for VYNE’s future developments.